coreSCD: multi-stakeholder consensus on core outcomes for sickle cell disease clinical trials

BACKGROUND: With the dramatic increase in the pipeline for new sickle cell disease (SCD) therapies in recent years, the time is ripe to ensure a robust body of evidence is available for decision making by regulators, payers, clinicians, and patients. Harmonization of the outcomes selected across int...

Descripción completa

Detalles Bibliográficos
Autores principales: Tambor, Ellen, Robinson, Matoya, Hsu, Lewis, Chang, Hsing-Yuan, Al Naber, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524872/
https://www.ncbi.nlm.nih.gov/pubmed/34666680
http://dx.doi.org/10.1186/s12874-021-01413-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524872/
https://www.ncbi.nlm.nih.gov/pubmed/34666680
http://dx.doi.org/10.1186/s12874-021-01413-8

Ejemplares similares